Yarrow Bioscience Inc (YARW) — Stock Valuation & Research

Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).

YARW key statistics

Price$17.37
Market cap$161.61M
SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
52-week range16.04-46.95
Dividend (TTM)$20.10 per share
Beta2.08

Explore YARW's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.